PROCEPT BioRobotics

PROCEPT BioRobotics is a commercial-stage medical device company specializing in surgical robotics for urology. Founded in 2009 and headquartered in San Jose, California, the firm focuses on developing transformative solutions for benign prostatic hyperplasia (BPH). The company is publicly traded on the NASDAQ under the ticker symbol PRCT. By integrating real-time multidimensional imaging with automated robotics, PROCEPT BioRobotics provides a proprietary platform that utilizes heat-free waterjet ablation for precise prostate tissue removal. This technology is engineered to deliver consistent, durable clinical outcomes regardless of prostate size or surgeon experience.

The organization operates with 500-1,000 employees, maintaining a robust manufacturing and engineering infrastructure to support its commercial-stage operations. Their primary product, an image-guided robotic system, represents a significant advancement in minimally invasive urologic surgery. By combining personalized treatment planning with automated robotic execution, the system addresses the limitations of traditional surgical methods. The company’s commitment to innovation is reflected in its ongoing development of medtech solutions that improve patient care and clinical efficiency. Meet PROCEPT BioRobotics's team to learn more about the leadership driving these technological advancements in the urology field.

PROCEPT BioRobotics has demonstrated significant market growth, reporting annual revenue of $337.3M. The company’s financial trajectory is supported by a history of strategic funding rounds, including significant capital from investors like T. Rowe Price and Perceptive Advisors. As a key player in the medical device sector, the firm competes with established entities such as Accuray and Advanced Urology Institute. Explore financial highlights to review detailed metrics regarding the company's fiscal performance andView more...